Sunovion Pharmaceuticals, based in Marlborough, Mass., will acquire Toronto-based Cynapsus Therapeutics for $624 million.
The companies signed a definitive agreement indicating Sunovion will pay $40.50 per share in cash for Cynapsus.
Through the deal, Sunovion will gain rights to Cynapsus' experimental drug APL-130277, intended to treat patients with Parkinson's disease. On Monday, the Food and Drug Administration granted Fast Track designation for the drug to expedite its development and approval.
The deal is expected to close in the fourth quarter of 2016.
More articles on supply chain:
FDA approves Novartis biosimilar copy of Amgen arthritis drug
Private investment firm places stake in Pennsylvania medical product company
Senators say Mylan's discount program, generic EpiPen only temporary solution